Literature DB >> 14557267

Interferon regulatory factor-3-mediated activation of the interferon-sensitive response element by Toll-like receptor (TLR) 4 but not TLR3 requires the p65 subunit of NF-kappa.

Claudia Wietek1, Sinead M Miggin, Caroline A Jefferies, Luke A J O'Neill.   

Abstract

Interferon regulatory factor (IRF) 3 is a transcription factor that binds the interferon-sensitive response element (ISRE) and is activated by Toll-like receptor 3 (TLR3) and TLR4. We have found that a dominant negative form of I kappa B kinase 2 and a mutant form of I kappa B, which acts as a super-repressor of NF-kappa B, blocked activation of the ISRE by the TLR4 ligand lipopolysaccharide but not the TLR3 ligand poly(I-C). TLR4 failed to activate the ISRE in mouse embryonic fibroblasts bearing a targeted deletion of p65, whereas the response to TLR3 in these cells was normal. The p65 subunit of NF-kappa B was detected in the lipopolysaccharide-activated but not poly(I-C)-activated ISRE-binding complex. Finally, p65 promoted transactivation of gene expression by IRF-3. These results therefore indicate that IRF-3-mediated activation of the ISRE by TLR4 but not TLR3 requires the p65 subunit of NF-kappa B.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557267     DOI: 10.1074/jbc.M308135200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Extensive cooperation of immune master regulators IRF3 and NFκB in RNA Pol II recruitment and pause release in human innate antiviral transcription.

Authors:  Jonathan E Freaney; Rebecca Kim; Roli Mandhana; Curt M Horvath
Journal:  Cell Rep       Date:  2013-08-29       Impact factor: 9.423

2.  Synthetic peptides containing ITIM-like sequences of IREM-1 (CD300F) differentially regulate MyD88 and TRIF-mediated TLR signalling through activation of SHP and/or PI3K.

Authors:  S-M Lee; K Suk; W-H Lee
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

3.  Nuclear factor κB subunits RelB and cRel negatively regulate Toll-like receptor 3-mediated β-interferon production via induction of transcriptional repressor protein YY1.

Authors:  Jakub Siednienko; Ashwini Maratha; Shuo Yang; Malgorzata Mitkiewicz; Sinéad M Miggin; Paul N Moynagh
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

4.  Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit.

Authors:  Shunbin Ning; Leslie E Huye; Joseph S Pagano
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 5.  Transcriptional control of the inflammatory response.

Authors:  Ruslan Medzhitov; Tiffany Horng
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

Review 6.  Crosstalk in NF-κB signaling pathways.

Authors:  Andrea Oeckinghaus; Matthew S Hayden; Sankar Ghosh
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

7.  IRF3 promotes adipose inflammation and insulin resistance and represses browning.

Authors:  Manju Kumari; Xun Wang; Louise Lantier; Anna Lyubetskaya; Jun Eguchi; Sona Kang; Danielle Tenen; Hyun Cheol Roh; Xingxing Kong; Lawrence Kazak; Rasheed Ahmad; Evan D Rosen
Journal:  J Clin Invest       Date:  2016-07-11       Impact factor: 14.808

8.  Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-κB Contributes to UV Radiation-Induced Immune Suppression.

Authors:  Wei Wang; Nicole M Chapman; Bo Zhang; Mingqi Li; Meiyun Fan; R Nicholas Laribee; M Raza Zaidi; Lawrence M Pfeffer; Hongbo Chi; Zhao-Hui Wu
Journal:  Cancer Res       Date:  2019-02-08       Impact factor: 12.701

Review 9.  NF-κB, inflammation, immunity and cancer: coming of age.

Authors:  Koji Taniguchi; Michael Karin
Journal:  Nat Rev Immunol       Date:  2018-01-22       Impact factor: 53.106

10.  SHPS-1 and a synthetic peptide representing its ITIM inhibit the MyD88, but not TRIF, pathway of TLR signaling through activation of SHP and PI3K in THP-1 cells.

Authors:  Eun-Ju Kim; Kyoungho Suk; Won-Ha Lee
Journal:  Inflamm Res       Date:  2013-01-12       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.